lapatinib has been researched along with lapatinib ditosylate in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (lapatinib ditosylate) | Trials (lapatinib ditosylate) | Recent Studies (post-2010) (lapatinib ditosylate) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 7 | 0 | 4 |
| Protein | Taxonomy | lapatinib (IC50) | lapatinib ditosylate (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0302 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0242 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.0163 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dohi, K; Haga, N; Iguchi, M; Inoue, M; Matsuo, K; Murashi, T; Ohara, T; Omori, N; Sentou, J; Shiota, T; Suzuki, N; Wada, T; Watanabe, F; Yari, H | 1 |
1 other study(ies) available for lapatinib and lapatinib ditosylate
| Article | Year |
|---|---|
Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases.
Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Mice; Microsomes, Liver; Models, Chemical; Neoplasm Transplantation; Pyrimidines; Rats; Receptor, ErbB-2; Structure-Activity Relationship | 2012 |